Kuhnast S. Anacetrapib reduces progression of athero- sclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin / S. Kuhnast, S. J. van der Tuin, J. W. van der Hoorn // Eur. Heart J. - 2015. - Vol. 36. - P. ...
To complicate matters, not all cholesterol contributes to heart and blood vessel problems. One type, called high-density lipoprotein (HDL) cholesterol, or "good cholesterol," actually lowers the risk of these problems. The other type, low-density lipoprotein (LDL) cholesterol, or "bad cholesterol...
353 mg % (-13%) and LDL decreased from 333 to 307 mg % (-8%). HDL cholesterol decreased approximately 35%. Thus, HMB appears to act differently from HMG in humans in that the effect is more pronounced and results in a specific decrease in LDL cholesterol but not in HDL cholesterol....
In addition to efficiently decreasing VLDL-triglycerides (TGs), fenofibrate increases HDL-cholesterol levels in humans. We investigated whether the fenofibrate-induced increase in HDL-cholesterol is dependent on the expression of the cholesteryl ester transfer protein (CETP). To this end, APOE*3-Leiden...
coronary artery disease, one group consumed 30 grams of pecans each day and another group consumed 30 ml of extra virgin olive oil every day. After 12 weeks, the pecan group saw a significant reduction in non-HDL cholesterol and in the ratio of total cholesterol to HDL (good cholesterol)....
Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk. Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AFH, de Graaf J. (Address: Division of Vascular Medicine, Department of General Internal Medicine; Depart... S Holewijn,MD ...
Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression Caroline C. van der Hoogt, 1, * ,† Willeke de Haan, 1, * ,† Marit Westerterp, * ,† Menno Hoekstra, § Geesje M. Dallinga-Thie,** Johannes A. Romijn, † Hans M. G. Princen, * ...
PROBLEM TO BE SOLVED: To provide a blood cholesterol-reducing agent capable of suppressing increase of blood lipid concentration by ingestion of dietary fat and reducing the level of blood fat amount and using a material derived from a natural product, and a composition capable of industrially effe...
Research outcomes will provide knowledge on effectiveness of MNT provision in reducing serum cholesterol, and feasibility, acceptability, and cost-effectiveness of delivering MNT via telehealth to address CVD risk in rural regions. Results will inform translation to health policy and practice for improving...
Oxxynea lowered plasma cholesterol and non-HDL cholesterol, but not HDL-cholesterol, and increased plasma antioxidant capacity. It also strongly reduced the area of aortic fatty streak deposition by 77%, cardiac production of superoxide anion by 45%, and p22phox subunit of NAD(P)H oxidase ...